Treatment of inflammatory myopathy with intravenous gamma globulin
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Intravenous immunoglobulin (IVlg) is a new modality used to help treat conditions associated with immune dysregulation. The inflammatory myopathies are a group of complex diseases .including dermatomyositis, polymyositis, and inclusion-body myositis. Overall evaluation of IVlg in myopathy has been hampered by difficulty in accurately diagnosing and assessing disease activity. The lack of large, well controlled, double-blind trials has precluded clear evaluation of the effectiveness of IVIg in these diseases. However, from the data presented in published reports, it appears that IVIg may be useful in the treatment of inflammatory myopathies, particularly dermatomyositis.
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To assess whether a new therapeutic modality is efficacious and should be used in clinical practice, every attempt should be made to apply strict diagnostic and prognostic criteria to the treated disease. Optimally, the clinician should be able to make a definite diagnosis, if necessary classifying and subclassifying the condition, to distinguish it from other similar diseases. One has to be able to accurately judge disease activity and to distinguish irreversible changes (ie, atrophy and scarring) from a potentially treatable inflammatory or infectious component One must critically assess the outcome of therapy, including short-and long-term advantages. A sound understanding of the mechanism of action of the treatment and its potential side effects are required.
Shortly after Tiselius and Kabat [1] demonstrated that antibodies are located in a fraction of gamma globulins, Cohn et at. [2, 3] developed methods by which plasma proteins could be separated into stable fractions with distinct biologic functions, setting the stage for the development of therapy with immunoglobulins. In 1952, Bruton [4] described the first agammaglobulinemic patient to be successfully treated with intramuscular injections of gamma globulin. The effectiveness of intramuscular gamma globulin in the treatment of agammaglobulinemic patients and subsequent reporting of increased numbers of antibody-deficient disorders made the need to develop a safe intravenous replacement more critical. Intravenous administration of immunoglobulins was established in clinical practice in 1962 [5] . At first, severe anaphylactoid reactions curtailed the use of intravenous immunoglobulin (IVIg) [6] . Early IVIg products were associated with severe reactions that were believed to be due to complementactivating IgG aggregates. Subsequently, the gamma globulin was modified by several techniques, including treatment at a low pH with traces of pepsin to eliminate aggregates without significantly changing antibody structure and function [7, 8] .
In the late 1970s, several IVIg preparations that were relatively free of side effects became available for clinical use [9, 10] . These immunoglobulins were primarily monomeric, with trace amounts of IgM and IgA. Adverse reactions were still reported in 10% to 15% of patients. However, these reactions were very rarely life threatening, characteristically causing tachycardia, chest tightness, backache, and fever, with normal or elevated blood pressure. Serious reactions with dyspnea, hypotension, and loss of consciousness were still rarely reported [11] [12] [13] [14] . Adverse reactions to IVIg usually can be managed by slowing the rate of intravenous infusion or discontinuing the therapy for a short period of time.
The efficacy of IVIg initially was believed to be due to passive replacement of deficient serum immunoglobulins [15] . However, it soon became apparent that IVIg may have other applications [16] [17] [18] . In 1981, Imbach et at. [19] reported successful treatment of children with idiopathic thrombocytopenic purpura using high-dose IVIg; Fe receptor blockage by IVIg, prolonging platelet survival, was believed to be responsible for this effect
The past decade has seen the use of IVIg expand to treat many autoimmune diseases ( with anti-idiotypic determinants could be used in the treatment of specific autoimmune conditions [22] . Immunosuppressant effects also may result if IVIg impedes major histocompatibility complex antigen presentation to T cells or interferes with T cell receptor binding by antireceptor antibody [16] [17] [18] . In summary, the mode of action of IVIg in the treatment of autoimmune diseases is thought to result from the restoration of idiotypic anti-idiotypic networks, suppression ofT lymphocytes, and solubilization of circulating immune complexes. Recent studies have shown that in dermatomyositis, IVIg may modulate the complement attack on the muscle cells. After IVIg therapy, repeat muscle biopsy studies showed the disappearance of membranolytic attack complex ( ie, C3b-C9 deposits) from endomysia! capillaries [26••] . 
Diagnosis of inflammatory myopathies
It has been recognized that the inflammatory muscle diseases differ from each other clinically and prognostically. As in many other diseases, there is still deficient understanding of etiologic factors . Thus, pathogenetic differences have been used for classification. Several mechanisms of immunologic dysregulation and autoantibody production, such as anti-Jo-1 antibody against histidyl-tRNA synthetase [27), virologic insults [28••,29•) , and associated malignant, collagen-vascular, or toxic conditions have been suggested. Needless to say, such complexity has led to significant difficulties in the classification of inflammatory myopathies, which was apparent in the classification criteria proposed recently [30) and in the criticism of this categorization [31) . Miller [32••) has listed 12 types of inflammatory myopathies and 10 serologic markers, some of which are "myositis-specific" and others "myositis-associated." New discoveries may substantially change our classification of myositis. For example, the relationship of intracellular inclusions to amyloidosis in inclusion-body myositis [33•] or the detection of human T celllymphotropic virus type I (HTLV-I) serologic markers, HTLV-I DNA in muscle biopsy, and HTLV-I glycoprotein 46 in the myocytes of Jamaican patients with polymyositis [29•] may necessitate reclassification of the inflammatory myopathies.
Activity of inflammatory myopathy
Myositis is a dynamic state in which an active inflammatory component is accompanied by progressive noninflammatory changes including atrophy and scarring. The distribution of these pathologic changes may vary from muscle to muscle and may occur in parallel within the same muscle. As many as 25o/o of muscle biopsy specimens may not show definite inflammatory changes, and electromyography may demonstrate a mixture of inflammatory and myopathic changes [34] . It has been suggested that the deltoid, paraspinal, and iliopsoas muscles are more useful for electromyographic studies than other muscles [35] . Biochemical markers such as creatine kinase level may be normal at diagnosis [34, 36) , and newly introduced tests for enzymes such as MB isoenzyme of creatine kinase or CA-111, although more specific, may not distinguish inflammatory myositis from other myopathies [37" ). The presence of autoantibodies and their titers does not necessarily correlate with disease activity [32••,34] . Clinical evaluation of muscle strength, although an important criterion of muscular power, cannot be used to reliably distinguish an active inflammatory process from atrophic changes and is limited by intra-and interobserver differences and the variety of different devices used for the measurements. Thus, it seems that reliable and sensitive indicators of disease activity in the overall assessment of myositis are still lacking.
Therapeutic trials
Corticosteroid use was suggested as the primary treatment of autoimmune inflammatory myopathy [38, 391 If this management is not effective or if patients develop undesirable side effects, other immunosuppressive agents may be added to the treatment, such as aza- Table 2 . The patients can be divided into at least six different clinical categories (Table 3) . Improvement was noted in about 71% of the patients. Notably, the best outcome was recorded for juvenile dermatomyositis and the worst for inclusion-body myositis. The main criticism of these clinical trials is that they were generally open, unblinded studies of small numbers of patients [53] . Usually, other drugs such as steroids were given simultaneously. The patients who were treated had heterogeneous conditions, including associated malignancy, collagen vascular disease, and presumed drug toxicity [30, 31] . Results were usually based on different variables, such as muscle strength or decrease in muscle enzymes, criteria which have been reported to be unreliable predictors of disease activity [34, 36] . Treatment with IVIg was given only after other immunosuppressive medications had failed in most patients, late in the disease course.
Other considerations that make comparative analysis difficult are variability in IVlg products infused, dosage, dose interval, and duration of treatment. Long-term outcome has not been assessed, and repeat muscle biopsies were usually not done. However, overall efficacy seems to be most promising in the treatment of juvenile dermatomyositis (Table 3 ) [43] [44] [45] . In one well designed double-blind placebo-controlled cross-over study, efficacy in nine of 12 dermatomyositis patients who were treated with high-dose IVIg (2 glkglmo) was demonstrated [43] . Muscle biopsy specimens showed decreased microvascular deposits, lymphocytic infiltrates, and necrotic muscle fibers, which were associated with a restoration of capillary circulation and increased size of surviving muscle fibers . There was also reduced expression of muscle major histocompatibility complex class I antigens. However, three of the above-mentioned 12 patients did not respond to IVIg treatment [43] .
Advantages and disadvantages
The advantage of IVIg therapy is the lack of serious adverse reactions. However, the results of recent studies suggest the possibility of transmission of hepatitis C virus [54",55"] . This factor should increase our awareness of the possible hazards and risks of intravenous infusion of immune serum globulins. The obvious drawbacks are the high cost of treatment and the need for intravenous access.
By testing various IVIg preparations and different dosages, it may be possible to identify products with the favorable immunologic profile necessary to treat inflammatory myopathy [16] [17] [18] . It is necessary to define differential dose responses to optimize therapy. It is also necessary to determine the total duration of treatment. The long-term prognosis for IVIg-treated patients is not known.
The time chosen to treat patients with inflammatory myopathy also may be an important consideration. IVIg treatment in dermatomyositis and polymyositis usually has been given only after other modalities have failed and the disease has been active for several months [42, [44] [45] [46] [47] 50, 51] . However, some studies have shown that early treatment would more likely result in disease control or possibly even in remission [56,57•] .
It may be possible to reverse the earliest signs of microangiopathy in dermatomyositis [26••] .
Conclusions
The role of IVIg in the treatment of inflammatory myopathy is still unclear. Although promising, until more exact pathologic mechanisms of the diseases are defined and a clearer definition of the various inflammatory myopathies completed, the therapeutic effectiveness of IVIg cannot be adequately assessed. However, it appears that IVIg may be useful in the treatment of inflammatory myopathies, and long-term, well controlled double-blind cross-over studies are needed.
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